
Small cell lung cancer still lacks predictive biomarkers, so comorbidities, performance status, and caregiver support drive treatment choices, while financial and logistical barriers threaten access to the newest options.

Small cell lung cancer still lacks predictive biomarkers, so comorbidities, performance status, and caregiver support drive treatment choices, while financial and logistical barriers threaten access to the newest options.

Maintenance therapy in extensive-stage disease now spans more than one immunotherapy backbone, but added efficacy arrives paired with added toxicity and cost, a trade-off that demands careful patient selection.

As evolving guidelines fold new regimens into category-one recommendations, keeping pace with which combinations qualify as frontline standard has become its own clinical and administrative challenge.

New data challenges a long-standing radiation practice: prophylactic cranial irradiation showed no survival benefit and worse cognitive outcomes, pushing the field toward closer monitoring instead of routine preventive treatment.

With comparable survival benefits and overlapping trial populations, choosing between two frontline immunotherapy regimens increasingly comes down to chemotherapy backbone flexibility and one drug's added indication across both disease stages.

Three-year survival data gives patients something rare in extensive-stage disease: a concrete number to hold onto. Nearly one in five patients alive at three years reframes what a durable tail of the curve can mean.

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in extensive-stage disease, giving clinicians flexibility while leaving progression-free survival largely unmoved.

Extensive-stage small cell lung cancer resisted immunotherapy's promise longer than its non-small cell counterpart, but a small, durable subset of long-term survivors justified testing checkpoint inhibitors against a historically difficult tumor.

Even with consolidation immunotherapy, most limited-stage patients still recur, a reminder that biomarker-driven approaches, earlier detection, and next-generation agents remain essential to moving survival further.

Logistics, not efficacy, often decide who completes limited-stage treatment. Distance from infusion centers, caregiver support, and clinic workflows can matter as much as the medicine itself in determining outcomes.

Despite a clear survival benefit, a meaningful share of eligible patients never receive consolidation immunotherapy after chemoradiation, exposing a gap between what trial data supports and what real-world practice actually delivers.

The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.

Payer step therapy and formulary limits reshape anti‑VEGF care—often raising long‑term costs and risking outcomes without doctor–payer alignment.

Experts question prior authorization for anti-VEGF retina drugs, urging outcome-based reviews and payer-physician dialogue to cut waste and costs.

Open-access anti‑VEGF choices cut delays in AMD, DME and RVO care, urging payer-physician collaboration for sustainable costs and better vision.

How longer-lasting anti-VEGF therapies cut injections, visits, and vision loss risk—why payers may save overall by covering newer retinal drugs.

Rising anti‑VEGF drug prices, Medicare copays, and travel burdens reshape retinal disease care—see how affordability drives real‑world treatment choices.

Concurrent chemoradiotherapy remains curative-intent therapy for limited-stage disease, yet cure rates without immunotherapy stall near thirty percent, a ceiling that scheduling choices and careful monitoring can only partly raise on their own.

Small cell lung cancer's stark divide between curable, localized disease and systemic, incurable disease shapes every treatment decision that follows, and screening gains are slowly shifting how many patients get caught early enough to benefit.

Learn how treat-and-extend anti-VEGF dosing cuts injections in retinal disease and why real-world evidence should guide payer access.

How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with new-generation treatments.

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Explore how high-dose aflibercept and dual-pathway faricimab boost anti-VEGF durability, targeting VEGF-A and Ang-2 for better retinal outcomes.

Clinicians tailor treat-and-extend anti-VEGF care, using newer agents to control faster and stretch injections to 20 weeks, reducing burden.

Learn how next‑gen anti‑VEGF therapies rapidly control wet AMD, DME and vein occlusion, cutting injections and protecting vision.

How treat-and-extend anti-VEGF care lowers injection burden and reshapes payer access decisions, guided by real-world evidence.

Experts explain how longer-lasting anti-VEGF injections reduce treatment burden and improve real-world vision outcomes in AMD, DME, and RVO.

Tara Graff shared her enthusiasm for the remarkable expansion of second-line treatment options that has occurred within a single year providing community oncologists with multiple highly effective, non-chemotherapy regimens that can be meaningfully tailored to individual patient characteristics and preferences, moving definitively away from a one-size-fits-all approach and toward truly personalized RRFL care.

Tara Graff outlined a practical framework for community oncology practices looking to establish safe and successful programs with novel regimens, emphasizing that while tafasitamab-based combinations can be adopted with relatively minimal operational changes, bispecific antibodies require more deliberate infrastructure investment, but that every community site has the capacity to build this capability with the right approach.

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of tafasitamab plus R² and the November 2025 approval of epcoritamab plus R² representing two major additions to the NCCN guidelines that meaningfully expand the second-line treatment options available to follicular lymphoma patients beyond the R² backbone and signaling a clear directional shift toward novel, non-chemotherapy combinations that can deliver progression-free survival measured in years.

May 15th 2025

August 13th 2026